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ABSTRACT
Introduction A better understanding of the molecular 
profile of bladder tumours, the identification of novel 
therapeutic targets, and introduction of new drugs and 
has renewed research interest in the field of bladder 
cancer. We describe the design and setup of a Dutch 
Prospective Bladder Cancer Infrastructure (ProBCI) as a 
means to stimulate and accelerate clinically meaningful 
experimental and observational research.
Methods and analysis ProBCI entails an open cohort 
of patients with bladder cancer in which the trials within 
cohorts (TwiCs) design can be embedded. Physicians 
in participating hospitals prospectively recruit invasive 
(≥T1) patients with bladder cancer on primary diagnosis 
for inclusion into the study. Extensive clinical data are 
collected and updated every 4 months, along with patient- 
reported outcomes and biomaterials. Informed consent 
includes participation in TwiCs studies and renewed 
contact for future studies. Consent for participation in 
questionnaires and molecular analyses that may yield 
incidental findings is optional.
Ethics and dissemination The Dutch ProBCI is a unique 
effort to construct a nation- wide cohort of patients with 
bladder cancer including clinical data, patient- reported 
outcomes and biomaterial, to facilitate observational and 
experimental research. Data and materials are available 
for other research groups on request through www. probci. 
nl. Ethics approval was obtained from METC Utrecht 
(reference: NL70207.041.19).
Trial registration number NCT04503577.
INTRODUCTION
After decades of limited progress, the field 
of bladder cancer is currently in motion. 
New therapeutic options were recently intro-
duced and there is a better understanding 
of the molecular profile of bladder tumours. 
Although these developments caused a wave 
of renewed research interest, they have yet to 
be translated into significant improvements 
for patients with bladder cancer.
Improved bladder cancer outcomes are 
imperative and long overdue, with survival 
having long been stable at dismal rates. 
Bladder cancer is among the top 10 most 
common malignancies with approximately 
550 000 annual new cases worldwide.1 Most 
patients (~70%) are diagnosed with non- 
muscle invasive bladder cancer (NMIBC: 
Ta, Tis, T1). NMIBC is characterised by high 
recurrence rates and the 5- year progres-
sion rates to muscle- invasive bladder cancer 
(MIBC) range from 7% among Ta tumours to 
20% among high- grade T1 tumours.2 Patients 
with MIBC have poor overall survival (approx-
imate 5- year survival rates of 40%) despite 
almost half of these patients undergoing 
radical cystectomy. To improve the survival of 
patients with bladder cancer, earlier detection 
is required and more effective local control 
with improved (neo)adjuvant, surgical and 
bladder- sparing treatment. Additionally, new 
therapies for metastatic disease are needed.3
The therapeutic landscape for bladder 
cancer is changing due to a shifting emphasis 
towards multimodal and bladder- preserving 
therapies in MIBC and several new therapeutic 
options for metastatic bladder cancer (mBC). 
New therapies include several checkpoint 
inhibitors (CPIs) that have been approved 
Strengths and limitations of this study
 ► First nation- wide trials within cohorts study for blad-
der cancer.
 ► Unique availability of combination of clinical data, 
biomaterials and patient- reported outcome mea-
sures for bladder cancer cohort.
 ► Data sharing and collaboration are encouraged.
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since 2017 for treatment in the metastatic setting, and 
targeted therapies such as fibroblast growth factor receptor 
(FGFR) inhibitors and enfortumab vedotin. CPIs have 
shown durable response in a proportion (~20%) of patients 
with mBC, but overall response rates remain modest.4 The 
introduction of these drugs was followed by a huge increase 
in the number of trials assessing the efficacy of these thera-
pies5 in both the muscle invasive (eg, as neoadjuvant treat-
ment) and non- muscle invasive settings. In addition, the 
efficacy of CPIs in conjunction with or sequentially after 
other treatments, including chemotherapy, radiotherapy 
and additional immunotherapeutic agents is currently 
being assessed in clinical trials.
Simultaneously, efforts are being undertaken to predict 
which patients are most likely to benefit from specific 
treatments through development of companion diagnos-
tics,6 as well as via assessing the predictive value of molec-
ular characteristics of bladder tumours.7 8 The various 
molecular subtypes that have recently been identified in 
urothelial cancer differ in underlying oncogenic mecha-
nisms, infiltration by immune and stromal cells, and histo-
logical and clinical characteristics as well as prognosis. 
However, apart from programmed death ligand 1 expres-
sion which exerts a mix of predictive and prognostic value 
for CPIs, this research has not yet yielded other clinically 
applicable predictors for treatment response.
Importantly, preclinical molecular findings have to 
be translated into a clinical application and eventually 
improve patient outcome, but this is hampered by several 
issues. The plethora of trials being executed among a 
limited proportion of the patient population results in 
slow patient accrual.9 In addition, considerable discrep-
ancies in characteristics between patients enrolled in 
trials and patients in clinical practice are present, thereby 
limiting generalisability and potentially validity.10–12
In addition to randomised clinical trials, observational 
research is important to guide bladder cancer manage-
ment. Approximately 85% of the evidence cited in the 
2020 European Association of Urology (EAU)- guidelines 
on MIBC and mBC is based on non- randomised studies, 
of which approximately half is based on observational 
research.13 Important observational research efforts 
focus on the identification of prognostic and predictive 
biomarkers. Experimental studies yield limited opportu-
nities in that area, because biomarker analysis are often 
only performed in the experimental arm and performed 
analyses lack comparability between trials.14 In contrast, 
observational studies on biomarkers dwindle because of 
the major efforts required for the execution of each indi-
vidual study (eg, patient recruitment and data and mate-
rial collection). Routine collection of biomaterials from 
unselected patient populations would accelerate these 
efforts and provide the necessary platform to validate 
findings.
Here we describe the Dutch Prospective Bladder Cancer 
Infrastructure (ProBCI) as a means to stimulate and 
accelerate clinical research, to ultimately improve patient 
outcomes. ProBCI aims to establish a cohort of patients 
with bladder cancer serving as an efficient starting point 
for observational research with readily available extensive 
clinical data reflecting daily clinical practice, patient- 
reported outcome measures (PROMs) and biomaterial. 
It will also serve as a source that enables a fast and less 
selected accrual of patients and historical or concurrent 
control groups for single arm intervention studies.
METHODS AND ANALYSIS
Study design
ProBCI constitutes an open cohort (figure 1), where newly 
diagnosed patients will be included continuously over 
time. In addition, the cohort serves as a basis to conduct 
interventional research according to the trials within 
cohort (TwiCs) design (also known as cohort multiple 
RCT, in short: cmRCT design).12 Under this design, all 
patients undergo standard of care by default. On initia-
tion of a randomised trial within the cohort, patients who 
meet the eligibility criteria can be (pre- )selected based on 
available clinical data and are subsequently randomised. 
Patients who are randomised to an experimental arm are 
contacted for the trial- specific informed consent, while 
Figure 1 The cohort multiple RCT design. cmRCT, cohort multiple RCT = Twics; IC, informed consent.
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those randomised to the control arm are not contacted 
and do not receive additional information.
Inclusion of patients and informed consent
All newly diagnosed patients of 18 years or older who 
provide written informed consent with high- risk non- 
muscle invasive bladder cancer (HR- NMIBC), MIBC and 
mBC, either urothelial or non- urothelial carcinoma, that 
is, all tumours of the bladder except pure Ta tumours, 
are eligible for inclusion in ProBCI by one of the partici-
pating hospitals. At the time of diagnosis or shortly there-
after, the patient is informed about the infrastructure. 
The information is provided by the treating physician (or 
research nurse/nurse specialist) after which the patient 
can decide about providing informed consent for the 
infrastructure. Informed consent for the ProBCI study 
covers the following aspects: (1) the linking and use of 
(clinical) data; (2) the overarching participation in the 
TwiCs design (broad consent15) including approval to 
serve as a control and approval to be contacted for future 
interventional research, either under the TwiCs design or 
otherwise; (3) longitudinal collection of liquid biopsie-
sand (4) use of residual tissue for research purposes. Two 
additional aspects of the informed consent are optional: 
(5) patients can provide consent for participation in ques-
tionnaires on health- related quality of life and (6) next- 
generation DNA and RNA sequencing that may yield 
incidental findings such as high- penetrance mutations 
for hereditary diseases. Included patients are entered in 
an online subject management system.
Data and biomaterial collection
The contents of the infrastructure include clinical data, 
PROMs and biomaterial. The Netherlands Comprehensive 
Cancer Organisation (IKNL) is an independent knowledge 
institute on oncological and palliative care in the Nether-
lands and provides a coordinating role in collection of data, 
PROMs and biomaterials based on the subject management 
system. Feasibility is achieved through central coordination 
that facilitates nation- wide identification of new patients 
with bladder cancer, clinical data collection within the Neth-
erlands Cancer Registry (NCR) framework and collection of 
PROMs within the PROFILES (Patient Reported Outcomes 
Following Initial treatment and Long term Evaluation of 
Survivorship) registry (a collaboration of IKNL and Tilburg 
University), without additional efforts from hospitals or 
clinicians.
Clinical data
The NCR forms the backbone of clinical data and will be 
complemented with other data sources where necessary. 
The NCR is managed by the IKNL. Data are collected 
from medical hospital files by independent data managers 
of the NCR and do not require any additional effort from 
the clinicians or patients. The NCR transcends hospital 
boundaries, so patient data can be collected covering 
the entire disease course. Clinical data include patient 
and tumour characteristics, treatment information and 
follow- up including recurrence and progression data, and 
will be updated every 4 months. Annually, patients in the 
NCR are linked with the Municipal Administrative Data-
base, in which death and emigration is recorded for all 
inhabitants of the Netherlands and patients’ vital statuses 
are updated in the NCR. For specific research questions, 
clinical data collection may be extended retrospectively 
or prospectively to cover additional items and clinical 
data may be enriched with data from additional sources.
Patient-reported outcomes
Patients are sent questionnaires for collection of PROMs 
shortly after diagnosis and after 6, 12 and 24 months. 
Additional questionnaire time points may be added rela-
tive to specific treatments. The questionnaire includes 
demographic questions, questions regarding comorbidi-
ties, the EQ- 5D- 5L,16 17 the EORTC QLQ- C30,18 the QLQ- 
NMIBC2419 and the QLQ- BLM30.20 Patients can choose 
to receive questionnaires on paper or by electronic mail.
Biomaterials
Biomaterials collected in the infrastructure include blood 
and tumour tissue. Peripheral blood will be collected 
shortly after diagnosis at a routine venipuncture moment. 
Genomic DNA will be isolated from whole blood and 
cell- free DNA from cell- free plasma. Additionally, blood 
collection in university hospitals will be extended to 
specific time points in relation to treatments as well 
(table 1). These include single timepoint collection 
of cell- free plasma after radical cystectomy or bladder- 
preserving therapy and longitudinal collection of cell- 
free plasma before, during and after systemic therapy for 
cell- free DNA analysis.
Ethics and governance
The ProBCI infrastructure received approval of the 
medical ethical review committee of the University Medical 
Center Utrecht, The Netherlands METC Utrecht), in 
February 2020 (protocol number NL70207.041.19). All 
intervention studies to be conducted within the infra-
structure (using the TwiCs design or otherwise) are 
required to obtain additional approval from a medical 
ethical review committee.
ProBCI is governed by the Foundation Prospective 
Bladder Cancer Infrastructure and a steering committee 
in which participating hospitals are represented. A 
sounding board provides input from the perspective of 
external experts, pharmaceutical companies and the 
bladder cancer patient association (Leven met Blaas- of Nier-
kanker). A scientific committee will review new research 
proposals based on scientific value.
Proceedings
Patient recruitment into ProBCI started in three academic 
hospitals (UMC Utrecht, Erasmus Medical Center, 
Radboud University Medical Center) in the Nether-
lands in October 2020. The expansion to other hospitals 
(both university medical centres and general hospitals) 
is ongoing and aims to ultimately cover the majority of 
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eligible patients. No end date or recruitment target is 
specified.
While coverage of prospectively included patients 
may be limited during the first year of ProBCI, longitu-
dinal clinical data will already be available for all eligible 
patients in the Netherlands through the NCR. This will 
cover the approximately 3200 people diagnosed annually 
with HR- NMIBC or MIBC the Netherlands. Additionally, 
extensive clinical data are retrospectively collected for all 
the patients with primary metastatic bladder cancer diag-
nosed from 2016 to 2019, covering approximately 350 
patients per year.
Data and material sharing
The ProBCI steering committee pursues its own research 
agenda, while also encouraging initiation of collabo-
rations and initiatives by external groups that may be 
eligible to use the ProBCI infrastructure for research 
purposes. Requests for data/material will be reviewed by 
the ProBCI scientific committee for scientific rigour and 
merit and by other bodies where applicable. These may 
include the NCR’s Supervisory Committee for compliance 
with NCR objectives and national privacy legislation and 
the Committee on Research with Human Subjects of the 
Radboud Biobank for legal and ethical aspects regarding 
biomaterials. More information on data requests, gover-
nance, research agenda and data and publication policy 
are available in online ( www. probci. nl).
Patient and public involvement
The bladder cancer patient association (Leven met 
Blaas- of Nierkanker) was involved in the design phase of 
the study, including proof reading of the patient infor-
mation material. As part of the ProBCI sounding board, 
they continue to provide additional input (eg, regarding 
research priorities, changes to the protocol) during the 
execution of the study. They also facilitate communica-
tion of the study’s research findings to patients through 
their channels.
Ethics and dissemination
ProBCI is the first initiative to construct a nation- wide 
cohort of patients with bladder cancer including clin-
ical data, PROMs and biomaterial to facilitate observa-
tional and experimental research. A similar initiative for 
colorectal cancer has provided the proof of feasibility 
of such a prospective cohort in the Netherlands.21 The 
ProBCI infrastructure aims to facilitate a wide range 
of possible observational and experimental research. 
Table 2 shows examples of topics that could be addressed 
through the infrastructure and below we further discuss 
the added value of the infrastructure, including obser-
vational studies, biomarker studies and interventional 
studies embedded within the TwiCs design.
The timely availability of an extensive set of specific 
clinical data from a large patient population could prove 
valuable in addressing knowledge gaps in the treatment 
of patients with bladder cancer through observational 
studies. Such studies could range from descriptive studies 
on the bigger picture (eg, the median time to develop-
ment of metastatic disease or long- term quality of life 
after bladder- preserving therapy) to predictive biomarker 
validation studies. Availability of biomaterial for a broad 
cohort of patients with bladder cancer undergoing 
various treatments with clinical outcomes could accel-
erate the identification and clinical validation of such 
biomarkers.22
In addition, observational research can carry out an 
important complementary role to RCTs. Comparative 
effectiveness studies in areas where trials have not (yet) 
been carried out may (temporarily) be the best available 
evidence yet and could be valuable if carried out timely 
and rigorously. Moreover, discrepancies often occur 
between clinical trial populations in which efficacy has 
been established, and the patient population in which 
interventions are applied.23 24 Specifically, study popula-
tions in trials supporting authorisation of CPIs in other 
malignancies were considerably younger than patients 
Table 1 Blood sample collection schedule by hospital type, patient subgroup and treatment
Subgroup Treatment Timing Blood
All hospitals       
  All patients All treatments  ► At diagnosis  ► Roche cell- free plasma (for cfDNA)
 ► EDTA whole blood (for genomic DNA)
University medical centres
  MIBC/mBC RC or BPT  ► 4–6 weeks after treatment  ► Roche cell- free plasma (for cfDNA)
  MIBC/mBC Neo- adjuvant 
chemotherapy
 ► Before initiation
 ► After two courses
 ► Before surgery
 ► Roche cell- free plasma (for cfDNA)
  All patients Checkpoint 
inhibitors
 ► Before initiation
 ► After two courses
 ► At first scan
 ► At progression
 ► Roche cell- free plasma (for cfDNA)

















pen: first published as 10.1136/bm





5Richters A, et al. BMJ Open 2021;11:e047256. doi:10.1136/bmjopen-2020-047256
Open access
in clinical practice.25 Validation of findings from trials in 
patient populations reflecting daily practice is therefore 
important.
The TwiCs design embedded in the cohort asserts 
advantages for efficient conduct of trials. After the first 
description in 2010,12 the TwiCs design has been success-
fully implemented in fields such as colorectal cancer, 
mental health and meniscus injuries.21 26–28 The major 
advantage of this design is its approach regarding patient 
accrual. Compared with RCTs, cohorts can recruit a larger 
number and more representative sample of patients.12 
By using such cohorts as a source for trials, we expect to 
increase the recruitment efficiency, reach and represen-
tativeness of trial populations. This should uphold the 
feasibility of the multitude of anticipated RCTs among 
the patients with bladder cancer,5 while providing a 
patient- centred approach to recruitment that is similar to 
routine healthcare.12 It takes away the barrier for patients 
to consent to randomisation with the risk of not being 
offered the preferred treatment29 and mitigates bias due 
to attrition and/or non- adherence.30 These advantages 
are set off against a loss in flexibility regarding the control 
treatment, which is by default the standard of care. The 
TwiCs design has recently been implemented in a local 
cohort with patients with bladder cancer in London, UK, 
providing first indications of feasibility of this approach in 
the context of bladder cancer.31
To summarise, we have established the Dutch ProBCI 
to collect real- world prospective clinical data and provide 
a continuous bladder cancer cohort for clinical trials. 
With the research opportunities that ProBCI provides, 
we aim to increase and accelerate the availability of 
robust evidence to clinical practice, ultimately leading to 
improved outcomes of patients with bladder cancer.
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Table 2 Examples of research topics within Prospective Bladder Cancer Infrastructure
Examples of research topics
Observational   
  Descriptive  ► The median time to development of metastatic disease in patients with primary and secondary 
muscle- invasive bladder cancer.
 ► The proportion of patients with metastatic bladder cancer treated with checkpoint inhibitors as first or 
second line therapy and survival outcomes.
  Effectiveness  ► Comparison of response rates and survival rates of patients treated with and without cisplatin- based 
chemotherapy in clinical practice to those in trial populations.
  Biomarkers  ► Predictive value of molecular subclass of muscle- invasive bladder cancer for response to 
neoadjuvant chemotherapy.
  PROMs  ► Quality of life of patients with muscle- invasive bladder cancer treated with radical cystectomy vs 
bladder- preserving therapy.
Interventional   
  Single arm study  ► Single- arm study of response rates to checkpoint inhibitors in patients with PD- L1 positive and 
negative metastatic bladder cancer.
 ► Comparison of response rates from single- arm study to concurrent controls from cohort with identical 
PD- L1 status.
  TwiCs study  ► Effectiveness of a protocol with liquid biopsies in combination with radiology compared with 
radiology alone for post- cystectomy monitoring of disease.
PD- L1, programmed death ligand 1; PROMs, patient reported outcome measures; TwiCs, trials within cohort.
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